| Cell cycle as a target of antineoplastic drugs. | |
| | |
MedLine Citation:
|
PMID: 20166983 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The cell cycle consists of a number of complex biochemical pathways that ensure that the start of a particular event depends on the successful and right end of previous steps in the pathway. An important role is played by cyclin/cyclin-dependent kinase (cdk) complexes which are critical regulators of cell cycle progression and RNA transcription. To ensure proper progression through each phase, cells have developed a series of orchestrated checkpoints that govern the different cellular kinases required for distinct cell cycle events. In particular, several cell cycle protein kinases, including members of the Aurora family and the Polo-like kinases, play critical roles in mitotic entry and chromosome segregation that ensure the correct formation of daughter cells. Tumour cell proliferation is frequently associated to both genetic and epigenetic mechanisms commonly affecting the expression of cell cycle regulatory proteins or causing an incompetent checkpoint control, resulting in aberrant responses to cellular damage. These alterations result not only in proliferative advantages but also in an increased susceptibility to the accumulation of additional genetic alterations that contribute to tumour progression and acquisition of more aggressive phenotypes. In the last years, the identification of anticancer drugs directed against critical cell cycle regulators has received particular attention. Specifically, several preclinical and clinical trials are addressing cdks or cell cycle protein kinase inhibitors. Starting from a description of cell cycle, this review summarizes the most recent studies on drugs targeting cell cycle regulators that are being used in cancer therapy. |
| | |
Authors:
|
Maria De Falco; Antonio De Luca |
Related Documents
:
|
17110183 - Dynamic green fluorescent protein sensors for high-content analysis of the cell cycle. 10066543 - Protein localization during the caulobacter crescentus cell cycle. 2476483 - Cognate interactions between helper t cells and b cells. iii. contact-dependent, lympho... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current pharmaceutical design Volume: 16 ISSN: 1873-4286 ISO Abbreviation: Curr. Pharm. Des. Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-05-27 Completed Date: 2010-08-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602487 Medline TA: Curr Pharm Des Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1417-26 Citation Subset: IM |
Affiliation:
|
School of Medicine, Second University of Naples Via L. Armanni, 5, 80138 Naples, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / pharmacology, therapeutic use* Cell Cycle / drug effects* Cell Cycle Proteins / antagonists & inhibitors Cell Line, Tumor Clinical Trials as Topic Humans Neoplasms / drug therapy*, enzymology, pathology Protein Kinases / metabolism Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Cell Cycle Proteins; EC 2.7.-/Protein Kinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nutlins and Ionizing Radiation in Cancer Therapy.
Next Document: PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-...